FIRST Psychotherapy for Youth Mental Health Issues
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how a new type of psychotherapy, called FIRST, can assist young people dealing with mental health issues such as anxiety, depression, or conduct problems. FIRST employs five key strategies to manage emotions and improve mental health, and its effects will be compared to standard therapy methods. The trial seeks participants who are fluent in English, aged 7 to 15, and have ongoing issues with anxiety, depression, or behavior. As an unphased trial, this study offers a unique opportunity to contribute to the development of innovative mental health therapies.
Will I have to stop taking my current medications?
The trial information does not specify whether participants must stop taking their current medications.
What prior data suggests that the FIRST psychotherapy approach is safe for youth?
Research has shown that the FIRST therapy program is generally safe for young people. Studies have found that therapists consider it easy to use and effective, with few reports of problems. No major safety concerns have been identified, and many therapists continue to incorporate it into their practice. FIRST is designed to address issues like anxiety, depression, and behavior problems by teaching skills such as staying calm and solving problems. It has been used successfully in various settings, demonstrating that young patients tolerate it well.12345
Why are researchers excited about this trial?
Researchers are excited about FIRST for youth mental health issues because it offers a fresh approach by focusing on five empirically supported principles of change. Unlike traditional therapies that might target a specific issue, FIRST is versatile and can address a wide range of problems like depression, anxiety, and conduct disorders. This adaptability is crucial for young people whose treatment needs can change during care. Additionally, FIRST uses a unique web-based feedback system to give therapists real-time data on their patients' progress, making it a dynamic and responsive treatment option.
What evidence suggests that this trial's treatments could be effective for youth mental health issues?
Research has shown that FIRST, one of the therapies studied in this trial, holds promise for treating mental health issues such as anxiety, depression, and behavior problems. Studies have found that it employs five main strategies to help children feel calmer, boost motivation, and improve problem-solving skills. In past trials, both young patients and therapists responded well to FIRST, achieving positive results in community mental health settings. The therapy emphasizes helping children manage their emotions, which is crucial for addressing these mental health challenges. Overall, FIRST offers a structured approach to effectively tackle a variety of emotional and behavioral issues in youth.15678
Are You a Good Fit for This Trial?
This trial is for children aged 7 to almost 16 who show signs of anxiety, depression, conduct issues, or post-traumatic stress but are generally in English-speaking classes. It's not for kids at immediate suicide risk, with eating disorders, schizophrenia-related conditions, autism spectrum disorder, intellectual disabilities needing special school classes or those referred only for ADHD symptoms.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either the FIRST transdiagnostic treatment or Usual Care (UC) for mental health issues
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- FIRST
- Usual Care
FIRST is already approved in United States, Canada for the following indications:
- Anxiety disorders
- Depressive disorders
- Conduct-related disorders
- Anxiety disorders
- Depressive disorders
- Conduct-related disorders
Find a Clinic Near You
Who Is Running the Clinical Trial?
Harvard University
Lead Sponsor
University of Texas at Austin
Collaborator